Health Products

Various Medical Devices Recalled by Respironics ( 2015-05-28)

· Published by Health Canada · Official notice

Details

Alert type: Medical Device Recall
Category: Medical Device
Issue: Medical Devices
Audience: General Public, Healthcare Professionals, Hospitals
Department: Health Canada
Hazard classification: Type II
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Products

Lot or serial numberBrand nameCompaniesModel or catalog number
AllH.OMNILAB ADVANCED, DOMESTIC CORE
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1043343
AllI.OMNILAB ADVANCED, CANADA
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1044278
AllF.BIPAP AUTOSV ADVANCED/ENCORE SMARTCARD/HEATED HUMIDIFIER
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1044289
AllG.OMNILAB ADVANCED, DOMESTIC
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1111122
AllD.BIPAP SYNCHRONY LAB SYSTEM
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1010771
AllE.BIPAP AUTOSV ADVANCED/ENCORE SMARTCARD
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1044288
AllB.BIPAP AUTOSV WITH SMARTCARD INT
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1038916
AllK.BIPAP AUTOSV ADVANCED SYSTEM ONE
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
CA951HS
AllC.BIPAP AUTOSV WITH SMARTCARD INT, CORE PACKAGE
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1040718
AllA.BIPAP AUTOSV
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1008628
AllJ.OMNILAB ADVANCED, CANADA CORE
Manufacturer
Respironics Inc.
1001 Murray Ridge Lane
Murraysville
15668
Pennsylvania
UNITED STATES
1044280

Introduction

Recalled Product
  1. BIPAP AUTOSV
  2. BIPAP AUTOSV WITH SMARTCARD INT
  3. BIPAP AUTOSV WITH SMARTCARD INT, CORE PACKAGE
  4. BIPAP SYNCHRONY LAB SYSTEM
  5. BIPAP AUTOSV ADVANCED/ENCORE SMARTCARD
  6. BIPAP AUTOSV ADVANCED/ENCORE SMARTCARD/HEATED HUMIDIFIER
  7. OMNILAB ADVANCED, DOMESTIC
  8. OMNILAB ADVANCED, DOMESTIC CORE
  9. OMNILAB ADVANCED, CANADA
  10. OMNILAB ADVANCED, CANADA CORE
  11. BIPAP AUTOSV ADVANCED SYSTEM ONE

Reason

Philips has become aware that ResMed has issued an urgent field safety notice that described a statistically significant 2.5 percent absolute increased annual risk of cardiovascular mortality for those randomized to a ResMed Adaptive Servo Ventilation (ASV) Therapy compared to the control group. In the patient population with reduced Left Ventricular Ejection Fraction (LVEF = 45%), 10.0 percent of the ASV group experienced a cardiovascular death each year compared to 7.5 percent of the control group, representing a 33.5 percent relative increased risk of cardiovascular mortality (HR=1.335, 95%CI=(1.070, 1.666), P-value= 0.010).

Philips is actively evaluating the information provided by ResMed and examining if this might impact the medical care of patients who use the Philips devices listed above. Until Philips completes our investigation, based on the ResMed announcement, Philips is strongly recommending that clinicians adhere to the following recommendations:

Do not place new patients with symptomatic chronic heart failure (NYHA 2-4) and reduced LVEF=45%, and moderate to severe predominant central sleep apnea on ASV therapy. Before putting patients on ASV, each patient should be assessed for heart failure. in case of signs and symptoms of heart failure an objective assessment of LVEF should be performed. Current patients should be evaluated and a discussion about whether to discontinue ASV therapy should occur if a current patient is found to be in the at-risk population. If it is unknown whether a current patient falls within the at-risk population, the patient should be evaluated to determine if ASV therapy should continue.
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime